Drug
Rivaroxaban
Rivaroxaban: highest development phase Approved, developed by Bayer, Johnson & Johnson, Lupin and others. 6 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Bayer, Johnson & Johnson, Lupin
Trials
| Drug | Phase | Indication |
|---|---|---|
| RIVAROXABAN | Approved | |
| XARELTO | Approved | |
| Rivaroxaban 10 MG NCT04662684 | Phase 3 | Covid19 |
| Rivaroxaban (Xarelto, BAY59-7939) NCT04720092 | Phase 1 | Thromboembolic Disorders |
| Rivaroxaban 15 mg NCT02289703 | Phase 1 | End-Stage Renal Disease |
| Rivaroxaban (Xarelto, BAY59-7939) NCT01853800 | Phase 1 | Biological Availability |
Latest
Follow Rivaroxaban on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.